文献速递胸部肿瘤

多肿瘤抑制基因共突变与EGFR突变肺癌患者不良结局相关

Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2023-10-06

纳入耶鲁癌症中心101例和美国癌症研究协会Project GENIE数据库182例接受EGFR酪氨酸激酶抑制剂(TKI)治疗的EGFR突变非小细胞肺癌(NSCLC)患者,按TP53及其他5个肿瘤抑制基因(TSG)改变分为三组。TP53mut/TSGmut组在一线TKI治疗中无进展生存期(PFS)和总生存期(OS)均劣于TP53mut/TSGwt组和TP53wt组,二线奥希替尼治疗及GENIE队列中亦见类似不良结局。

要点

  • TP53mut/TSGmut肿瘤患者接受EGFR TKI治疗结局最差。
  • 一线TKI治疗中,TP53mut/TSGmut组PFS较TP53mut/TSGwt组缩短(HR=2.03)。
  • TP53mut/TSGmut组OS较TP53wt组缩短(HR=2.54)。

核心结论

  • TP53mut/TSGmut肿瘤患者构成一个侵袭性疾病表型亚组,接受EGFR TKI治疗结局较差。
  • 该信息有助于理解TKI治疗差异结局的生物学基础,并对识别可能从奥希替尼单药以外治疗干预中获益的患者有意义。

研究设计与样本

  • 纳入接受EGFR TKI治疗且具有肿瘤基因组分析结果的EGFR突变NSCLC患者。
  • 按TP53及另外5个TSG(RB1、NF1、ARID1A、BRCA1和PTEN)改变将队列分为三组:TP53mut/TSGmut、TP53mut/TSGwt和TP53wt。
  • 在耶鲁癌症中心101例和美国癌症研究协会Project GENIE数据库182例两个独立队列中评估患者特征和临床结局。

主要发现

  • 耶鲁队列中,65例(64%)检出TP53突变,其中23例为TP53mut/TSGmut,42例为TP53mut/TSGwt。
  • 二线奥希替尼治疗及GENIE队列中亦见TP53mut/TSGmut肿瘤患者结局较差。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with metastatic EGFR-mutant NSCLC inevitably have disease progression while on tyrosine kinase inhibitor (TKI) therapy. Co-occurring tumor suppressor gene (TSG) alterations have been associated with poor outcomes, however, detailed analyses of their impact on patient outcomes are limited. METHODS: Patients with EGFR-mutant NSCLC treated with EGFR TKIs who had tumor genomic profiling were included. Alterations in TP53 and five additional TSGs (RB1, NF1, ARID1A, BRCA1, and PTEN) were used to stratify the cohort into the following three subgroups: patients with tumors harboring a TP53 mutation plus a mutation in at least one additional TSG (TP53mut/TSGmut), those having a TP53 mutation without additional TSG mutations (TP53mut/TSGwt), and those with TP53wt. Patient characteristics and clinical outcomes were assessed in two independent cohorts. RESULTS: A total of 101 patients from the Yale Cancer Center and 182 patients from the American Association for Cancer Research Project GENIE database were included. In the Yale cohort, TP53 mutations were identified in 65 cases (64%), of which 23 were TP53mut/TSGmut and 42 were TP53mut/TSGwt. Although the presence of a TP53 mutation was associated with worse outcomes, the additional TSG alteration in TP53mut tumors identified a subset of patients associated with particularly aggressive disease and inferior clinical outcome in both the Yale and the GENIE cohorts. Specifically, in the Yale cohort for patients receiving first-line TKIs, those with TP53mut/TSGmut tumors had shorter progression-free survival (PFS) and overall survival (OS) than TP53mut/TSGwt (PFS: hazard ratio [HR] = 2.03, confidence interval [CI]: 1.12-3.69, p < 0.01, OS: HR = 1.58, CI: 0.82-3.04, p = 0.12) or TP53wt cases (PFS: HR 2.4, CI: 1.28-4.47, p < 0.001, OS: HR = 2.54, CI: 1.21-5.34, p < 0.005). Inferior outcomes in patients with TP53mut/TSGmut tumors were also found in those receiving osimertinib as second-line therapy. Similar findings were seen in patients in the GENIE cohort. CONCLUSIONS: Patients with TP53mut/TSGmut tumors represent a patient subgroup characterized by an aggressive disease phenotype and inferior outcomes on EGFR TKIs. This information is important for understanding the biological underpinnings of differential outcomes with TKI treatment and has implications for identifying patients who may benefit from additional therapeutic interventions beyond osimertinib monotherapy.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Stockhammer P, Grant M, Wurtz A, et al. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer. J Thorac Oncol. 2023. PMID: 37806385. doi:10.1016/j.jtho.2023.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。